Other News To Note
Tuesday, August 14, 2012
NPS Pharmaceuticals Inc., of Bedminster, N.J., said that the Prescription Drug User Fee Act action date for its NDA for Gattex (teduglutide) for the treatment of adult patients with short bowel syndrome has been extended by three months to Dec. 30.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.